Nalbuphine extended release - Trevi Therapeutics

Drug Profile

Nalbuphine extended release - Trevi Therapeutics

Alternative Names: Nalbuphine ER; Nalbuphine extended-release; PW-4142; T 111

Latest Information Update: 19 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Penwest Pharmaceuticals
  • Developer Endo Pharmaceuticals; Trevi Therapeutics
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists; Opioid mu receptor antagonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prurigo nodularis; Pruritus
  • Discontinued Pain

Most Recent Events

  • 24 Apr 2018 Trevi Therapeutics plans the phase II/III PRISM trial for Prurigo nodularis in June 2018 (PO) (NCT03497975)
  • 20 Jul 2017 Trevi Therapeutics completes a phase II/III trial for Prurigo nodularis in Germany, Poland and Austria (PO) (EudraCT2013-005628-41)
  • 13 Oct 2016 Efficacy data and adverse event data from a phase II trial in Prurigo Nodularis were released by Trevi Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top